Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy

FundingWire.com brief · 46m ago · 1 min read · via cnbc.com

The telehealth company will now offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are approved by the FDA.

The telehealth company will now offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are approved by the FDA. This story matters for Finance & Markets readers tracking finance. Reported by cnbc.com. Read the full original at the source link below.

Originally reported by cnbc.com. FundingWire.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily finance & markets signal

More from FundingWire.com

Related ventures